This week's briefing is here with fresh GLP-1 pill updates, muscle-saving habits, and FDA safety label changes. # Weekly Briefing: Aug 24, 2026 **TL;DR:** Foundayo oral pill remains the only no-restriction GLP-1 option, muscle protection comes down to protein + resistance, and FDA clarified suicide-risk language this year. ## 💊 GLP1 News ### New research & approvals On April 1, 2026, the FDA approved orforglipron (Foundayo, Lilly) for treating obesity or overweight with weight-related complications. It is the first small-molecule oral nonpeptide GLP-1 receptor agonist, and is described as the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions. Foundayo follows Novo Nordisk's oral Wegovy, approved in December 2025 as the first oral GLP-1 for weight loss, making it the second pill option in the class. ### Weight management tips Two strategies stand out to prevent lean-mass loss: adequate protein and resistance training. Evidence tables list resistance training as preserving lean mass alongside adequate protein intake 1.2–1.6 g/kg/day to support muscle protein synthesis. Clinicians note “Exercise (particularly strength training) plays a critical role in preserving lean muscle mass while on GLP-1 medications”. Practical for your membership: 25-30g protein per meal spread through the day, 2-3 full-body strength sessions weekly, walk 10 minutes after eating. ### Side effects & safety On Jan 13, 2026, the FDA asked drugmakers to remove label warnings about potential risk of suicidal thoughts from GLP-1 weight-loss drugs, including Wegovy and Zepbound. The agency said its evaluation did not identify an increased risk of suicidal ideation or behavior with use. Separately, FDA added a class-wide counseling note about pulmonary aspiration risk during general anesthesia or deep sedation — tell any surgical team you are on a GLP-1, use only approved prescriptions, eat smaller slower meals, and stay hydrated. ## 💪 Mindset reminders to be strong and positive